A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors

The PRAME tumor antigen is a potential target for immunotherapy. We assessed the immunogenicity, the antitumor activity, and the safety and the tolerability of a recombinant PRAME protein (recPRAME) combined with the AS15 immunostimulant (recPRAME+AS15) in preclinical studies in mice and Cynomolgus...

Descripción completa

Detalles Bibliográficos
Autores principales: Gérard, Catherine, Baudson, Nathalie, Ory, Thierry, Segal, Lawrence, Louahed, Jamila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Basic Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661047/
https://www.ncbi.nlm.nih.gov/pubmed/26325375
http://dx.doi.org/10.1097/CJI.0000000000000095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661047/
https://www.ncbi.nlm.nih.gov/pubmed/26325375
http://dx.doi.org/10.1097/CJI.0000000000000095

Ejemplares similares